ACR open rheumatology · 2026
A Novel Use of Anifrolumab for a Novel Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Holtz Zachary, Schulz Adam, Meara Alexa
Аннотация
OBJECTIVE: To explore the potential role of type-I interferon (IFN-I) signaling in autoimmune cytopenias outside the context of systemic lupus erythematosus (SLE), and to evaluate the clinical response to off-label anifrolumab in two patients with fatigue and immune-mediated cytopenias who did not meet established criteria for SLE.
METHODS: We describe two older White male patients with fatigue and autoimmune cytopenias who did not meet established SLE criteria and were refractory to standard immunosuppressants. Both received off-label anifrolumab.
RESULTS: Both patients experienced rapid and sustained improvement in fatigue and resolution of cytopenias following treatment, with continued benefit and no significant adverse effects.
CONCLUSION: These cases suggest IFN-I signaling may underlie autoimmune cytopenias outside classic SLE. The positive response to anifrolumab raises the possibility of an atypical or distinct IFN-mediated autoimmune condition and supports broader investigation of IFN blockade in hematologic autoimmunity.
METHODS: We describe two older White male patients with fatigue and autoimmune cytopenias who did not meet established SLE criteria and were refractory to standard immunosuppressants. Both received off-label anifrolumab.
RESULTS: Both patients experienced rapid and sustained improvement in fatigue and resolution of cytopenias following treatment, with continued benefit and no significant adverse effects.
CONCLUSION: These cases suggest IFN-I signaling may underlie autoimmune cytopenias outside classic SLE. The positive response to anifrolumab raises the possibility of an atypical or distinct IFN-mediated autoimmune condition and supports broader investigation of IFN blockade in hematologic autoimmunity.